Abstract: A gondola car has a door and an associated door frame the end. The door hangs hingedly from the header of the frame. The header runs across the top of the door opening and is connected to the top chords at either side. The door posts are positioned inside the side sheets and tie into the header at each upper corner. The side sheets lap onto the door posts to allow longitudinal adjustment of the side assemblies and the door frame relative to each other, at assembly. The side posts are connected to the header with a tie plate that is bolted to both members. The car may also have a tarp dome at each end. The tarp dome has non-welded connections that have play to permit the tarp dome to accommodate movement of the top chords.

Abstract: Described herein is a computer implemented method for managing a repository that includes one or more component packages and a repository configuration file listing repository dependencies. Each component package has a package configuration file listing package dependencies. The method including the steps of: parsing the repository configuration file; aliasing a package dependency listed in the repository configuration file with at least two repository dependency aliases; parsing a package configuration file; and linking each repository dependency alias to a package dependency listed in the package configuration file.

Abstract: Described herein is a computer implemented method and a computer system for processing a modification to a first repository, the first repository including components that are used in a second repository. The method comprises executing an integrator service that is communicatively coupled to the first repository and to the second repository; the integrator service detecting the modification to the first repository; the integrator service causing generation of an integrated repository by integration of the detected modification into the second repository; and the integrator service triggering processing of the integrated repository.

Abstract: Described herein is a computer implemented method for managing a repository that includes one or more component packages and a repository configuration file listing repository dependencies. Each component package has a package configuration file listing package dependencies. The method including the steps of: parsing the repository configuration file; aliasing a package dependency listed in the repository configuration file with at least two repository dependency aliases; parsing a package configuration file; and linking each repository dependency alias to a package dependency listed in the package configuration file.

Abstract: A gondola car has a door and an associated door frame the end. The door hangs hingedly from the header of the frame. The header runs across the top of the door opening and is connected to the top chords at either side. The door posts are positioned inside the side sheets and tie into the header at each upper corner. The side sheets lap onto the door posts to allow longitudinal adjustment of the side assemblies and the door frame relative to each other, at assembly. The side posts are connected to the header with a tie plate that is bolted to both members. The car may also have a tarp dome at each end. The tarp dome has non-welded connections that have play to permit the tarp dome to accommodate movement of the top chords.

Abstract: A gondola car has a door and an associated door frame the end. The door hangs hingedly from the header of the frame. The header runs across the top of the door opening and is connected to the top chords at either side. The door posts are positioned inside the side sheets and tie into the header at each upper corner. The side sheets lap onto the door posts to allow longitudinal adjustment of the side assemblies and the door frame relative to each other, at assembly. The side posts are connected to the header with a tie plate that is bolted to both members. The car may also have a tarp dome at each end. The tarp dome has non-welded connections that have play to permit the tarp dome to accommodate movement of the top chords.

Abstract: A gondola car has a door and an associated door frame the end. The door hangs hingedly from the header of the frame. The header runs across the top of the door opening and is connected to the top chords at either side. The door posts are positioned inside the side sheets and tie into the header at each upper corner. The side sheets lap onto the door posts to allow longitudinal adjustment of the side assemblies and the door frame relative to each other, at assembly. The side posts are connected to the header with a tie plate that is bolted to both members. The car may also have a tarp dome at each end. The tarp dome has non-welded connections that have play to permit the tarp dome to accommodate movement of the top chords.

Abstract: A drop-center rail road freight car may have a gondola body for carrying lading, which may have end sections and a deep central section therebetween. The body may include a decking or floor structure, and longitudinally extending side beams bordering the floor structure. The car may have U-shaped bending-moment transmitting cross-bearers. The cross-bearers and side beam stiffeners may have inner and outer flange continuity such as to transmit a bending moment. The car may have stub sills. The stub sills may each have an inboard gooseneck that extends downward and inboard. The gooseneck may have a longitudinally extending portion that connects to the endmost cross-bearer of the central portion of the car. The main shear plate may lap the side sills, and may be bent downwardly to mate with the end margins of the side sheet lower portion to form a converging box-like truncated pyramidal structure.

Abstract: A drop-center rail road freight car may have a gondola body for carrying lading, which may have end sections and a deep central section therebetween. The body may include a decking or floor structure, and longitudinally extending side beams bordering the floor structure. The car may have U-shaped bending-moment transmitting cross-bearers. The cross-bearers and side beam stiffeners may have inner and outer flange continuity such as to transmit a bending moment. The car may have stub sills. The stub sills may each have an inboard gooseneck that extends downward and inboard. The gooseneck may have a longitudinally extending portion that connects to the endmost cross-bearer of the central portion of the car. The main shear plate may lap the side sills, and may be bent downwardly to mate with the end margins of the side sheet lower portion to form a converging box-like truncated pyramidal structure.

Abstract: The present invention relates to novel classes of compounds which are inhibitors of interleukin-1? converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against IL-1-, apoptosis-, IGIF-, and IFN-?-mediated diseases, inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, degenerative diseases, and necrotic diseases. This invention also relates to methods for inhibiting ICE activity, for treating interleukin-1-, apoptosis-, IGIF- and IFN-?-mediated diseases and decreasing IGIF and IFN-? production using the compounds and compositions of this invention.

Abstract: The present invention relates to novel classes of compounds which are inhibitors of interleukin-1? converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against IL-1-, apoptosis-, IGIF-, and IFN-?-mediated diseases, inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, degenerative diseases, and necrotic diseases. This invention also relates to methods for inhibiting ICE activity, for treating interleukin-1-, apoptosis-, IGIF- and IFN-?-mediated diseases and decreasing IGIF and IFN-? production using the compounds and compositions of this invention.

Abstract: The present invention relates to novel classes of compounds which are inhibitors of interleukin-1? converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against IL-1-, apoptosis-, IGIF-, and IFN-?-mediated diseases, inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, degenerative diseases, and necrotic diseases. This invention also relates to methods for inhibiting ICE activity, for treating interleukin-1-, apoptosis-, IGIF- and IFN-?-mediated diseases and decreasing IGIF and IFN-? production using the compounds and compositions of this invention.

Abstract: A series of 5,6-dihydro-1,3-benzothiazol-7(4H)-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted morpholin-4-yl moiety, being selective inhibitors of PD kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.

Abstract: The present invention relates to novel classes of compounds which are inhibitors of interleukin-1? converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against IL-1-, apoptosis-, IGIF-, and IFN-?-mediated diseases, inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, degenerative diseases, and necrotic diseases. This invention also relates to methods for inhibiting ICE activity, for treating interleukin-1-, apoptosis-, IGIF- and IFN-?-mediated diseases and decreasing IGIF and IFN-? production using the compounds and compositions of this invention.

Abstract: A series of 5,6-dihydro-1,3-benzothiazol-7(4H)-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted morpholin-4-yl moiety, being selective inhibitors of PD kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.

Abstract: Pyrimidines of formula (1) are described 1

Abstract: The present invention relates to novel classes of compounds which are inhibitors of interleukin-1&bgr; converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against IL-1-, apoptosis-, IGIF-, and IFN-&ggr;-mediated diseases, inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, degenerative diseases, and necrotic diseases. This invention also relates to methods for inhibiting ICE activity, for treating interleukin-1-, apoptosis-, IGIF- and IFN-&ggr;-mediated diseases and decreasing IGIF and IFN-&ggr; production using the compounds and compositions of this invention.

Abstract: Fused polycyclic 2-aminopyrimidines of formula (1): wherein Ar is an optionally substituted aromatic or heteroaromatic group; X is a carbon or nitrogen atom; Y is a carbon or nitrogen atom; Z is a linker group; A together with X and Y forms an optionally substituted monocyclic or bicyclic aromatic or heteroaromatic group; and the salts, solvates, hydrates and N-oxides thereof are described. The compounds are potent and selective inhibitors of the protein tyrosine kinases p56lck and p59fyn and are of use in the prophylaxis and treatment of immune diseases, hyperproliferative disorders and other diseases in which inappropriate p56lck and/or p59fyn activity is believed to have a role.

Abstract: Pyrimidines of formula (1) are described wherein Ar is an optionally substituted aromatic or heteroaromatic group; R1 is a hydrogen atom or a straight or branched chain alkyl group; R2 is a —X1—R3 group where X1 is a direct bond or a linker atom or group, and R3 is an optionally substituted aliphatic, cycloaliphatic, heteroaliphatic, heterocycloaliphatic, aromatic or heteroaromatic group; and the salts, solvates, hydrates and N-oxides thereof. The compounds are selective KDR Kinase and/or FGFr Kinase inhibitors and are of use in the prophylaxis and treatment of disease states assoicated with angiogenesis.

Abstract: Compounds of general formula (1) are described wherein: Ar is an optionally substituted aromatic group; R2 is a hydrogen or halogen atom or a group —X1—R2a where X1 is a direct bond or a linker atom or group, and R2a is an optionally substituted straight or branched chain alkyl, alkenyl or alkynyl group; R3 is an optionally substituted heterocycloalkyl group; and the salts, solvates, hydrates and N-oxides thereof. The compounds are selective protein tyrosine kinase inhibitors, particularly the kinases ZAP-70 and syk and are of use in the prophylaxis and treatment of immune or allergic diseases and diseases involving inappropriate platelet activation.